Rhythm Pharmaceuticals, Inc. (RYTM) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Rhythm Pharmaceuticals reported revenue of $189.8M, up 45.8% from $130.1M the year before. Net income was -$196.5M (a -103.6% net margin), or -$3.11 per diluted share. Gross margin was 89.7% and operating margin was -101.2%. Operating activities generated -$115.7M of cash, leaving -$116.6M of free cash flow. At fiscal year end, Rhythm Pharmaceuticals held $480.2M in total assets against $210.2M in total liabilities, including $54.3M of cash and equivalents.
Open the full interactive Rhythm Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Rhythm Pharmaceuticals Key Stats
| Share Price | $86.61 |
|---|---|
| Market Cap | $5.94B |
| Revenue YoY Growth | +45.8% |
| 52-Week Range | $75.82 – $117.62 |
| Shares Outstanding | 68.6 million (basic, 2026 Q2) |
Rhythm Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $3.2M | $23.6M | $77.4M | $130.1M | $189.8M |
| Cost of Goods Sold | — | $599,000 | $2.1M | $9.3M | $13.4M | $19.5M |
| Gross Profit | — | $2.6M | $21.5M | $68.1M | $116.8M | $170.3M |
| Operating Income | -$136.6M | -$170.1M | -$179.2M | -$184.4M | -$265.5M | -$192.0M |
| Pre-Tax Income | -$134.0M | -$69.6M | -$181.1M | -$184.1M | -$260.3M | -$196.0M |
| Income Tax | — | — | — | $564,000 | $346,000 | $497,000 |
| Net Income | -$134.0M | -$69.6M | -$181.1M | -$184.7M | -$260.6M | -$196.5M |
| Diluted EPS | -$3.04 | -$1.40 | -$3.47 | -$3.20 | -$4.34 | -$3.11 |
Rhythm Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $51.3M | $57.3M | $60.1M | $71.3M |
| Net Income | -$52.9M | -$47.5M | -$55.6M | -$49.3M |
| Diluted EPS | -$0.82 | -$0.73 | -$0.83 | -$0.73 |
Rhythm Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $100.9M | $59.2M | $127.7M | $60.1M | $89.1M | $54.3M |
| Current Assets | $181.7M | $308.4M | $354.2M | $308.3M | $374.2M | $466.9M |
| Total Assets | $187.1M | $329.5M | $382.5M | $332.7M | $392.3M | $480.2M |
| Current Liabilities | $18.0M | $43.4M | $39.8M | $55.2M | $115.5M | $105.9M |
| Total Long-Term Debt | — | — | — | — | $109.8M | $108.2M |
| Total Liabilities | $20.5M | $45.4M | $118.2M | $163.0M | $227.7M | $210.2M |
| Shareholders' Equity | $166.5M | $284.2M | $264.3M | $169.8M | $21.7M | $139.1M |
Rhythm Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$122.0M | -$146.0M | -$173.4M | -$136.2M | -$113.9M | -$115.7M |
| Cash From Investing | $158.5M | -$62.2M | $28.0M | -$5.7M | -$48.2M | -$137.2M |
| Cash From Financing | $2.0M | $166.5M | $213.8M | $74.4M | $191.2M | $218.0M |
| Free Cash Flow | -$122.2M | -$146.4M | -$173.7M | -$136.2M | -$113.9M | -$116.6M |
Figures from Rhythm Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Rhythm Pharmaceuticals financials page for every line item.
Rhythm Pharmaceuticals Company Profile
| Ticker | RYTM |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001649904 |
Frequently Asked Questions
What was Rhythm Pharmaceuticals' revenue in fiscal 2025?
Rhythm Pharmaceuticals (RYTM) reported revenue of $189.8M for fiscal 2025.
What is Rhythm Pharmaceuticals' annual revenue history?
Rhythm Pharmaceuticals' annual revenue by fiscal year: 2020: $0; 2021: $3.2M; 2022: $23.6M; 2023: $77.4M; 2024: $130.1M; 2025: $189.8M.
What was Rhythm Pharmaceuticals' net income in fiscal 2025?
Rhythm Pharmaceuticals reported net income of -$196.5M for fiscal 2025.
What was Rhythm Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Rhythm Pharmaceuticals' diluted EPS was -$3.11 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Rhythm Pharmaceuticals generate in fiscal 2025?
Rhythm Pharmaceuticals generated -$116.6M of free cash flow in fiscal 2025.
What was Rhythm Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Rhythm Pharmaceuticals reported revenue of $71.3M.
How much debt does Rhythm Pharmaceuticals have?
Rhythm Pharmaceuticals reported $108.2M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Rhythm Pharmaceuticals are outstanding?
Rhythm Pharmaceuticals reported a weighted average of 68.6 million basic shares outstanding in 2026 Q2.
What is Rhythm Pharmaceuticals' market cap?
Based on its latest closing price, Rhythm Pharmaceuticals (RYTM) has a market capitalization of about $5.94B.
When does Rhythm Pharmaceuticals' fiscal year end?
Rhythm Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Rhythm Pharmaceuticals headquartered?
Rhythm Pharmaceuticals lists its business address in Boston, Massachusetts in its SEC filings.